相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Nagilactone E suppresses TGF-β1-induced epithelial-mesenchymal transition, migration and invasion in non-small cell lung cancer cells
Le-Le Zhang et al.
PHYTOMEDICINE (2019)
Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling
Jiao Wu et al.
NATURE (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
BORIS promotes chromatin regulatory interactions in treatment-resistant cancer cells
David N. Debruyne et al.
NATURE (2019)
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
Khyati N. Shah et al.
NATURE MEDICINE (2019)
New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer
Anushka Dongre et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Osimertinib resistance in non-small cell lung cancer: Mechanisms and therapeutic strategies
Zheng-Hai Tang et al.
CANCER LETTERS (2018)
Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors
Cecilia Lopez Sambrooks et al.
CANCER RESEARCH (2018)
Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype
Jing Xu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2018)
Toosendanin, a natural product, inhibited TGF-1-induced epithelial-mesenchymal transition through ERK/Snail pathway
Weiwei Luo et al.
PHYTOTHERAPY RESEARCH (2018)
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma A Systematic Review and Meta-analysis
Chee Khoon Lee et al.
JAMA ONCOLOGY (2018)
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Zofia Piotrowska et al.
CANCER DISCOVERY (2018)
Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma
Mau-Ern Poh et al.
JOURNAL OF THORACIC DISEASE (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer
Pei-Chih Lee et al.
CANCER CELL (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
Matthew J. Hangauer et al.
NATURE (2017)
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Vasanthi S. Viswanathan et al.
NATURE (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
NF-kappaB Is Involved in the Regulation of EMT Genes in Breast Cancer Cells
Bruno R. B. Pires et al.
PLOS ONE (2017)
Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells
Xiao-Ming Jiang et al.
ACTA PHARMACOLOGICA SINICA (2017)
Epithelial-mesenchymal transition: a new target in anticancer drug discovery
Fabrizio Marcucci et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance
Ching-Feng Chiu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming
Praveena S. Thiagarajan et al.
ONCOTARGET (2016)
Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line
Zheng-Hai Tang et al.
ONCOTARGET (2016)
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
Matthew G. Oser et al.
LANCET ONCOLOGY (2015)
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
Xiaofeng Zheng et al.
NATURE (2015)
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
Kari R. Fischer et al.
NATURE (2015)
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Matthew J. Niederst et al.
NATURE COMMUNICATIONS (2015)
NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
Collin M. Blakely et al.
CELL REPORTS (2015)
Targeting molecular addictions in cancer
I. Vivanco
BRITISH JOURNAL OF CANCER (2014)
Molecular mechanisms of epithelial-mesenchymal transition
Samy Lamouille et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non-Small-Cell Lung Cancer Cells
Masakuni Serizawa et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
The complexity of NF-κB signaling in inflammation and cancer
Bastian Hoesel et al.
MOLECULAR CANCER (2013)
A Correction to the Research Article Titled: "Inositol Polyphosphate Multikinase Is a Coactivator of p53-Mediated Transcription and Cell Death" by R. Xu, N. Sen, B. D. Paul, A. M. Snowman, F. Rao, M. S. Vandiver, J. Xu, S. H. Snyder
Science Signaling (2013)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Trever G. Bivona et al.
NATURE (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
Zhan Yao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Shared principles in NF-κB signaling
Matthew S. Hayden et al.
CELL (2008)
NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression
MA Huber et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Secreted transforming growth factor β2 activates NF-κB, blocks apoptosis, and is essential for the survival of some tumor cells
T Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
分享论文
